The suggested method can separate the anabolic androgenic steroids in sports supplements, using a simple, fast, and efficient sample preparation procedure that guarantees accurate results.
Different combinations of organic solvents (e.g., chloroform-acetone-ethyl acetate-n-hexane) in various volume compositions were used in this study. The optimal mobile phase for the ten steroids at the beginning is chloroform/acetone (9: 1). Using this eluent solvent, five AASs get separated (19-nor androstenedione, 19-nortestosterone, stanozolol, oxymetholone, and oxandrolone) and five other AASs (methyl testosterone, clostebol, trenbolone enanthate, testosterone enanthate, and nandrolone decanoate) appear as two bands. In order to separate these five AASs, the plate was transferred to another tank, and a second eluent solvent system used ethyl acetate/n-hexane (6.5: 3.5) to separate methyl testosterone, clostebol, and trenbolone enanthate or cyclohexane/ethyl acetate/methanol (8: 2: 0.5) to separate testosterone enanthate and nandrolone decanoate.
The retardation factor of each standard is listed in
Table 1, based on the specific mobile phase mentioned below. Also, chromatograms of all analytes with peak purity chart were placed in the Supplementary File.
At the end of the chromatographic run, the plates were visualized at 254 nm. The plates were also immersed in sulphuric acid solution (10% in methanol) and then visualized at 366 nm and visible light. All the AASs appeared as clear spots at 254 nm except oxandrolone and stanozolol. Oxandrolone and stanozolol can be identified at 366 nm only after spraying sulphuric acid solution and can be dried in the oven at 100°C for 10 minutes. Quantifying all steroids was performed using the wavelength of 254 nm except for oxandrolone and stanozolol, which are quantified after immersing the plate in sulphuric acid solution (10% in methanol) and measurement of absorbance at 366 nm.
The HPTLC-chromatographic method was validated based on the ICH guidelines in terms
of specificity, linearity, limit of quantification, limit of detection, accuracy, and precision (
27).
The first step of the method development was determining the LOD and the LOQ for each hormone.
Table 3 presents the LODs and LOQs for the AASs included in the screening.
| Compound | Limit of Detection (μg on the spot) | Limit of Detection (μg/g = ppm of supplement) | Limit of Quantitation (μg on the spot) | LOQ (μg/g = ppm of supplement) |
|---|
| 19-nor androstenedione | 0.04 | 40 | 0.14 | 140 |
| 19-nortestosterone | 0.04 | 40 | 0.14 | 140 |
| Methyltestosterone | 0.02 | 20 | 0.06 | 60 |
| Clostebol | 0.02 | 20 | 0.06 | 60 |
| Trenbolone enanthate | 0.02 | 20 | 0.06 | 60 |
| Stanozolol | 0.02 | 20 | 0.06 | 60 |
| Oxymetholone | 0.16 | 160 | 0.5 | 500 |
| Oxandrolone | 0.04 | 40 | 0.14 | 140 |
| Testosterone enanthate | 0.02 | 20 | 0.06 | 60 |
| Nandrolone decanoate | 0.02 | 20 | 0.06 | 60 |
Table 2 shows linearity parameters (slopes, intercepts, and correlation coefficients obtained on three different supplements) for each AAS included in the present study. The method showed good linearity over the range from the LOQ of each steroid to 1000 μg.g
-1 of nutritional supplement.
As mentioned before, the precision of the method was determined through intra-day precision (repeatability) and inter-day precision: By studying the samples of whey protein at levels of 0.2 and 0.4 μg/spot three times on the same day (intra-day precision) and by studying the same samples on three different days over a period of three weeks (inter-day precision).
Table 4 shows the results of the precision studies expressed as the coefficient of variation of the measured peak area (%CV) for AASs in the analyzed samples at two different concentrations. The accuracy of this method was calculated through the recovery study and expressed as the percent recovery of AASs at each concentration level. Percent recovery was assessed by comparing the peak area from the spiked samples to standard solutions at equivalent concentrations at three different concentrations, i.e., 0.01, 0.02, and 0.05 μg.mL
-1, by triplicate analyses on three different days. The results of concentration levels for each AAS are summarized in
Table 4.
| Compounds | Inter-day Precision (%CV of Peak Area) | Intra-day Precision (%CV of Peak Area) | Recovery (%) |
|---|
| 19-nor androstenedione | 0.72 - 7.57 | 7.57 - 11.58 | 98.12 - 113.25 |
| 19-nortestosterone | 1.15 - 1.26 | 4.58 - 12.37 | 97.7 - 114.41 |
| Methyltestosterone | 2.58 - 5.03 | 6.58 - 7.61 | 98.61 - 105.48 |
| Clostebol | 1.13 - 1.38 | 3.04 - 6.73 | 99.48 - 101.5 |
| Trenbolone enanthate | 4.02 - 4.11 | 0.35 - 1.75 | 99.5 - 101.6 |
| Stanozolol | 4.28 - 5.03 | 0.45 - 1.4 | 99.12 - 103.84 |
| Oxymetholone | 0.67 - 3.16 | 4.7 - 6.7 | 98.74 - 108.66 |
| Oxandrolone | 1.48 - 3.09 | 3.78 - 10.75 | 99 - 106.81 |
| Testosterone enanthate | 6.66 - 7.10 | 10.33 - 12.01 | 94.21 - 105.44 |
| Nandrolone decanoate | 7.38 - 8.84 | 7.86 - 13.82 | 99.27 - 106.07 |